Literature DB >> 11438468

High expression of the trefoil protein TFF1 in interval breast cancers.

M Crosier1, D Scott, R G Wilson, C D Griffiths, F E May, B R Westley.   

Abstract

Breast cancer screening is important for the early detection of breast cancer. Tumors that become symptomatic in the screening interval are known as interval cancers but the reasons for their rapid progression are unknown. Estrogen receptor expression is lower in interval cancers suggesting that they may have reduced hormonal responsiveness. To investigate this hypothesis we have measured the expression of the estrogen receptor and three estrogen-responsive genes (cathepsin D, progesterone receptor, and TFF1) in screen-detected and interval breast cancers. The expression of the protease cathepsin D was not associated with estrogen receptor in either group of tumor. Progesterone receptor expression was highly correlated with that of the estrogen receptor in both groups of tumors but it was not expressed at significantly different levels in the two groups of tumors. Expression of TFF1, a cellular motogen, was correlated with estrogen receptor in screen-detected but not interval cancers and was expressed at markedly higher levels in interval breast tumors, the group that expresses lower levels of estrogen receptor. Interval cancers are characterized by high levels of expression of TFF1 and/or Ki67 suggesting that cell migration and cell division play important roles in the rapid progression of interval cancers. The observation that TFF1 expression in interval cancers tends to be estrogen-independent and that interval cancers have reduced estrogen receptor expression suggests they may have a reduced response to hormone therapy.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11438468      PMCID: PMC1850420          DOI: 10.1016/S0002-9440(10)61687-2

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  24 in total

1.  The human trefoil peptide, TFF1, is present in different molecular forms that are intimately associated with mucus in normal stomach.

Authors:  J L Newton; A Allen; B R Westley; F E May
Journal:  Gut       Date:  2000-03       Impact factor: 23.059

2.  Identification and characterization of estrogen-regulated RNAs in human breast cancer cells.

Authors:  F E May; B R Westley
Journal:  J Biol Chem       Date:  1988-09-15       Impact factor: 5.157

3.  Differences in Ki67 and c-erbB2 expression between screen-detected and true interval breast cancers.

Authors:  M Crosier; D Scott; R G Wilson; C D Griffiths; F E May; B R Westley
Journal:  Clin Cancer Res       Date:  1999-10       Impact factor: 12.531

4.  A secreted glycoprotein induced by estrogen in human breast cancer cell lines.

Authors:  B Westley; H Rochefort
Journal:  Cell       Date:  1980-06       Impact factor: 41.582

5.  Breast cancer-associated pS2 protein: synthesis and secretion by normal stomach mucosa.

Authors:  M C Rio; J P Bellocq; J Y Daniel; C Tomasetto; R Lathe; M P Chenard; A Batzenschlager; P Chambon
Journal:  Science       Date:  1988-08-05       Impact factor: 47.728

6.  Dimerization of human pS2 (TFF1) plays a key role in its protective/healing effects.

Authors:  T Marchbank; B R Westley; F E May; D P Calnan; R J Playford
Journal:  J Pathol       Date:  1998-06       Impact factor: 7.996

7.  Interval breast cancer: a more aggressive subset of breast neoplasias.

Authors:  R DeGroote; B F Rush; J Milazzo; M J Warden; J M Rocko
Journal:  Surgery       Date:  1983-10       Impact factor: 3.982

8.  pS2 expression and response to hormonal therapy in patients with advanced breast cancer.

Authors:  L H Schwartz; F C Koerner; S M Edgerton; J M Sawicka; M C Rio; J P Bellocq; P Chambon; A D Thor
Journal:  Cancer Res       Date:  1991-01-15       Impact factor: 12.701

9.  The 5' flanking region of the pS2 gene contains a complex enhancer region responsive to oestrogens, epidermal growth factor, a tumour promoter (TPA), the c-Ha-ras oncoprotein and the c-jun protein.

Authors:  A M Nunez; M Berry; J L Imler; P Chambon
Journal:  EMBO J       Date:  1989-03       Impact factor: 11.598

10.  The occurrence of interval cancers in the Nijmegen screening programme.

Authors:  P H Peeters; A L Verbeek; J H Hendriks; R Holland; M Mravunac; G P Vooijs
Journal:  Br J Cancer       Date:  1989-06       Impact factor: 7.640

View more
  8 in total

1.  Differential expression of prognostic biomarkers between interval and screen-detected breast cancers: does age or family history matter?

Authors:  Jan T Lowery; Tim Byers; John Kittelson; John E Hokanson; Judy Mouchawar; John Lewin; Dan Merrick; Lisa Hines; Meenakshi Singh
Journal:  Breast Cancer Res Treat       Date:  2011-03-24       Impact factor: 4.872

2.  The effect of a DNA repair gene on cellular invasiveness: XRCC3 over-expression in breast cancer cells.

Authors:  Veronica L Martinez-Marignac; Amélie Rodrigue; David Davidson; Martin Couillard; Ala-Eddin Al-Moustafa; Mark Abramovitz; William D Foulkes; Jean-Yves Masson; Raquel Aloyz
Journal:  PLoS One       Date:  2011-01-24       Impact factor: 3.240

3.  Deficiency in trefoil factor 1 (TFF1) increases tumorigenicity of human breast cancer cells and mammary tumor development in TFF1-knockout mice.

Authors:  E Buache; N Etique; F Alpy; I Stoll; M Muckensturm; B Reina-San-Martin; M P Chenard; C Tomasetto; M C Rio
Journal:  Oncogene       Date:  2011-02-28       Impact factor: 9.867

4.  TFF3 is a valuable predictive biomarker of endocrine response in metastatic breast cancer.

Authors:  Felicity E B May; Bruce R Westley
Journal:  Endocr Relat Cancer       Date:  2015-04-21       Impact factor: 5.678

5.  TFF1 and TFF3 mRNAs Are Higher in Blood from Breast Cancer Patients with Metastatic Disease than Those without.

Authors:  Marwa H Elnagdy; Omar Farouk; Amal K Seleem; Hoda A Nada
Journal:  J Oncol       Date:  2018-06-07       Impact factor: 4.375

6.  VULCAN integrates ChIP-seq with patient-derived co-expression networks to identify GRHL2 as a key co-regulator of ERa at enhancers in breast cancer.

Authors:  Andrew N Holding; Federico M Giorgi; Amanda Donnelly; Amy E Cullen; Sankari Nagarajan; Luke A Selth; Florian Markowetz
Journal:  Genome Biol       Date:  2019-05-13       Impact factor: 13.583

7.  The trefoil factor interacting protein TFIZ1 binds the trefoil protein TFF1 preferentially in normal gastric mucosal cells but the co-expression of these proteins is deregulated in gastric cancer.

Authors:  Felicity E B May; S Michael Griffin; Bruce R Westley
Journal:  Int J Biochem Cell Biol       Date:  2008-08-03       Impact factor: 5.085

8.  Circular RNA hsa_circ_0061825 (circ-TFF1) contributes to breast cancer progression through targeting miR-326/TFF1 signalling.

Authors:  Gaofeng Pan; Anwei Mao; Jiazhe Liu; Jingfeng Lu; Junbin Ding; Weiyan Liu
Journal:  Cell Prolif       Date:  2020-01-21       Impact factor: 6.831

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.